Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Who’s ready to start the week comparing data on two rival cancer drugs from studies featuring different trial designs?
OK, I’ll do it anyway.
Loxo Oncology $LOXO and Blueprint Medicines $BPMC have been duking it out with their early-stage studies on their RET inhibitors, and they were both back at it with updates for mutant medullary thyroid cancer at the American Thyroid Association meeting over the weekend.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.